Antitumor effect of cell therapy with mesenchymal stem cells on murine melanoma B16-F10

Imagem de Miniatura
Arquivos
art_MENEZES_Antitumor_effect_of_cell_therapy_with_mesenchymal_stem_2020.PDF.pdf (12.25 MB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
Autores
CABRAL, Laertty Garcia de Sousa
PETRELLIS, Maria Carla
MARIA, Durvanei Augusto
Citação
BIOMEDICINE & PHARMACOTHERAPY, v.128, article ID 110294, 12p, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
In this study, the antitumor and immunomodulatory effects of mesenchymal stem cells (MSC) obtained from bone marrow in the treatment of dorsal melanoma B16-F10. The MSC cells were obtained from the bone marrow of isogenic C57BL/6J mice, characterized and inoculated by two routes, intratumor (it) and intravenous (iv). The hematological profile, expression markers and receptors, phases of the cell cycle and mitochondrial electrical potential were evaluated by flow cytometry. The dorsal tumor mass showed a significant reduction after treatment by the two routes of administration with a significant effect by the intravenous route. MSC showed immunomodulatory potential and did not induce an increase in the markers involved in tumor control and progression. The number of cells in the sub-G1 phase increased significantly after treatments compared to the control group. The percentage of cells in phases GO/G1, S and G2/M decreased, with only the group (it) showing a significant reduction. The intratumor group showed a significant decrease in the G2/M phase. Treatment with MSC provided a significant decrease in the percentage of metabolically active tumor cells, demonstrating its intrinsic effect in the control of cell proliferation. Regarding the mechanism of cell death, MSCs modulated the expression of proteins involved in the regulation of the cell cycle, angiogenesis receptors and pro-apoptotic proteins by intrinsic and extrinsic routes. Therefore, the use of undifferentiated MSC, administered intratumor and intravenous is possibly a promising treatment for melanoma.
Palavras-chave
Tumor, Melanoma, Mesenchymal stem cells, Immunomodulatory, Apoptosis
URI
https://observatorio.fm.usp.br/handle/OPI/37721
Referências
  1. Abdi R, 2008, DIABETES, V57, P1759, DOI 10.2337/db08-0180
  2. Ahn JO, 2015, ANTICANCER RES, V35, P159
  3. Bao Q, 2012, STEM CELLS DEV, V21, P2355, DOI 10.1089/scd.2012.0060
  4. Barkholt L, 2013, CYTOTHERAPY, V15, P753, DOI 10.1016/j.jcyt.2013.03.005
  5. BEATTIE CW, 1988, SEMIN ONCOL, V15, P500
  6. BERNENGO MG, 1983, CANCER, V52, P1841, DOI 10.1002/1097-0142(19831115)52:10<1841::AID-CNCR2820521014>3.0.CO;2-N
  7. Bolognia J.L., 2017, DERMATOLOGY E BOOK
  8. Bydlowski Sergio P., 2009, Rev. Bras. Hematol. Hemoter., V31, P25
  9. Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657
  10. Corsten MF, 2008, LANCET ONCOL, V9, P376, DOI 10.1016/S1470-2045(08)70099-8
  11. ebertinga Cherly Lee D., 2004, J DERMATOL, V31, P299
  12. Ennis WJ, 2013, ADV WOUND CARE, V2, P369, DOI 10.1089/wound.2013.0449
  13. Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
  14. Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7
  15. Ghaedi M, 2011, J GENE MED, V13, P171, DOI 10.1002/jgm.1552
  16. Goncalves FD, 2014, WORLD J GASTROENTERO, V20, P18228, DOI 10.3748/wjg.v20.i48.18228
  17. Javan MR, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00840
  18. Mahla Ranjeet Singh, 2016, INT J CELL BIOL, DOI [10.1155/2016/6940283, DOI 10.1155/2016/6940283]
  19. Martin FT, 2010, BREAST CANCER RES TR, V124, P317, DOI 10.1007/s10549-010-0734-1
  20. Mirzaei H, 2016, CURR MED CHEM, V23, P455, DOI 10.2174/0929867323666151217122033
  21. Najafabadi MM, 2018, CELL J, V20, P19, DOI 10.22074/cellj.2018.4924
  22. Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716
  23. Ramdasi Sushilkumar, 2015, Int J Hematol Oncol Stem Cell Res, V9, P95
  24. Read J, 2013, AUSTRALAS J DERMATOL, V54, P163, DOI 10.1111/ajd.12013
  25. Richetta AG, 2014, ONCOLOGY-BASEL, V86, P104, DOI 10.1159/000356878
  26. Roorda BD, 2009, CRIT REV ONCOL HEMAT, V69, P187, DOI 10.1016/j.critrevonc.2008.06.004
  27. Russo FP, 2006, GASTROENTEROLOGY, V130, P1807, DOI 10.1053/j.gastro.2006.01.036
  28. Schatton T, 2008, PIGM CELL MELANOMA R, V21, P39, DOI 10.1111/j.1755-148X.2007.00427.x
  29. Schmidt A, 2006, EUR J CELL BIOL, V85, P1179, DOI 10.1016/j.ejcb.2006.05.015
  30. Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
  31. Sortino-Rachou AM, 2011, CAD SAUDE PUBLICA, V27, P565, DOI 10.1590/S0102-311X2011000300016
  32. Sun B, 2005, STEM CELLS DEV, V14, P292, DOI 10.1089/scd.2005.14.292
  33. Teo AKK, 2010, BIOCHEM J, V428, P11, DOI 10.1042/BJ20100102
  34. TOI M, 1994, JPN J CANCER RES, V85, P1045, DOI 10.1111/j.1349-7006.1994.tb02904.x
  35. Uder C, 2018, CYTOM PART A, V93A, P32, DOI 10.1002/cyto.a.23239
  36. Yarak S, 2010, AN BRAS DERMATOL, V85, P647, DOI 10.1590/S0365-05962010000500008
  37. Zago M.A., 2004, SEMINARIO I FERNANDO, P23

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/53
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03